Evidence map›Paper›PMID 31859216›Full record

Observational studyThe Lancet. Infectious diseases2020

Clinical characteristics of enterovirus A71 neurological disease during an outbreak in children in Colorado, USA, in 2018: an observational cohort study.

Kevin Messacar, Emily Spence-Davizon, Christina Osborne, Craig Press, Teri L Schreiner, Jan Martin, Ricka Messer, John Maloney, Alexis Burakoff, Meghan Barnes and 10 more

Open access · greenAbstract readObservational Study
In one paragraph

Observational study in The Lancet. Infectious diseases, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
9.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it, 103 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Prevalence and epidemiology of enterovirus species in a pediatric oncology patient population.Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology · 2025
    Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Review
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

20 authors at 4 institutions in 1 country.

Kevin MessacarSection of Infectious Diseases, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA. Electronic address: kevin.messacar@childrenscolorado.org.
Emily Spence-DavizonColorado Department of Public Health and the Environment, Denver, CO, USA.
Christina OsborneSection of Infectious Diseases, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Craig PressSection of Child Neurology, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Teri L SchreinerSection of Child Neurology, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Jan MartinSection of Child Neurology, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Ricka MesserSection of Child Neurology, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
John MaloneySection of Radiology, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Alexis BurakoffColorado Department of Public Health and the Environment, Denver, CO, USA; Centers for Disease Control and Prevention, Atlanta, GA, USA.
Meghan BarnesColorado Department of Public Health and the Environment, Denver, CO, USA.
Shannon RogersCenters for Disease Control and Prevention, Atlanta, GA, USA.
Adriana S LopezCenters for Disease Control and Prevention, Atlanta, GA, USA.
Janell RouthCenters for Disease Control and Prevention, Atlanta, GA, USA.
Susan I GerberCenters for Disease Control and Prevention, Atlanta, GA, USA.
M Steven ObersteCenters for Disease Control and Prevention, Atlanta, GA, USA.
W Allan NixCenters for Disease Control and Prevention, Atlanta, GA, USA.
Mark J AbzugSection of Infectious Diseases, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Kenneth L TylerDepartment of Pediatrics and Department of Neurology, School of Medicine, University of Colorado, Aurora, CO, USA.
Rachel HerlihyColorado Department of Public Health and the Environment, Denver, CO, USA.
Samuel R DominguezSection of Infectious Diseases, School of Medicine, University of Colorado, Aurora, CO, USA; Children's Hospital Colorado, Aurora, CO, USA.
Centers for Disease Control and Prevention · USChildren's Hospital Colorado · USColorado Department of Public Health and Environment · USUniversity of Colorado Denver · US

Funding

Implementation and Effectiveness of a Rapid Cerebrospinal Fluid Diagnostics Program for Children with Suspected Central Nervous System InfectionK23AI128069 · NIAID · UNIVERSITY OF COLORADO DENVER · PI MESSACAR, KEVIN BRETT · 2017 to 2021
$878k
Intramural CDC HHS CC999999
6 · The paper itself

Abstract

backgroundIn May, 2018, Children's Hospital Colorado noted an outbreak of enterovirus A71 (EV-A71) neurological disease. We aimed to characterise the clinical features of EV-A71 neurological disease during this outbreak.

methodsIn this retrospective observational cohort study, children (younger than 18 years) who presented to Children's Hospital Colorado (Aurora, CO, USA) between March 1 and November 30, 2018, with neurological disease (defined by non-mutually exclusive criteria, including meningitis, encephalitis, acute flaccid myelitis, and seizures) and enterovirus detected from any biological specimen were eligible for study inclusion. The clinical characteristics of children with neurological disease associated with EV-A71 were compared with those of children with neurological disease associated with other enteroviruses during the same period. To explore the differences in clinical presentation of acute flaccid myelitis, we also used a subgroup analysis to compare clinical findings in children with EV-A71-associated acute flaccid myelitis during the study period with these findings in those with enterovirus D68 (EV-D68)-associated acute flaccid myelitis at the same hospital between 2013 and 2018.

findingsBetween March 10 and Nov 10, 2018, 74 children presenting to Children's Hospital Colorado were found to have enterovirus neurological disease; EV-A71 was identified in 43 (58%) of these children. The median age of the children with EV-A71 neurological disease was 22·7 months (IQR 4·0-31·9), and most of these children were male (34 [79%] children). 40 (93%) children with EV-A71 neurological disease had findings suggestive of meningitis, 31 (72%) children showed evidence of encephalitis, and ten (23%) children met our case definition of acute flaccid myelitis. All children with EV-A71 disease had fever and 18 (42%) children had hand, foot, or mouth lesions at or before neurological onset. Children with EV-A71 disease were best differentiated from those with other enteroviruses (n=31) by the neurological findings of myoclonus, ataxia, weakness, and autonomic instability. Of the specimens collected from children with EV-A71, this enterovirus was detected in 94% of rectal, 79% of oropharyngeal, 56% of nasopharyngeal, and 20% of cerebrospinal fluid specimens. 39 (93%) of 42 children with EV-A71 neurological disease who could be followed up showed complete recovery by 1-2 months. Compared with children with EV-D68-associated acute flaccid myelitis, children with EV-A71-associated acute flaccid myelitis were younger, showed neurological onset earlier after prodromal symptom onset, had milder weakness, showed more rapid improvement, and were more likely to completely recover.

interpretationThis outbreak of EV-A71 neurological disease, the largest reported in the Americas, was characterised by fever, myoclonus, ataxia, weakness, autonomic instability, and full recovery in most patients. Because EV-A71 epidemiology outside of Asia remains difficult to predict, identification of future outbreaks will be aided by prompt recognition of these distinct clinical findings, testing of non-sterile and sterile site specimens, and enhanced enterovirus surveillance.

fundingNone.

Indexed as

Child, PreschoolColoradoDisease OutbreaksEnterovirusEnterovirus InfectionsFemaleHumansInfantMaleNervous System DiseasesRetrospective Studies

Identifiers

PMID31859216
PMCPMC11284833
OpenAlexW2994709146

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.